Ferrovial S.A. (0P2N)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 41.70 |
|---|---|
| 52-week range | 41.70 – 63.52 |
| Return, 1 month / 3 months | +0.0% / +0.0% |
| Return, 1 year / 3 years | −22.3% / +58.7% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 117.9% |
| Worst drawdown (1 year) | -33.4% |
| Average daily value traded | 15.93M EUR |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ferrovial is a Spanish infrastructure group based in Madrid that designs, builds and operates transport infrastructure. Its activities cover toll roads, airports, highways and related services, with much of its work carried out through long-term concessions under which it manages and maintains the assets it develops. The company serves public authorities and institutional clients in Spain and in several other countries, and it also provides construction and maintenance services for civil engineering projects.
On this site Ferrovial S.A. appears as a stock on the London Exchange (UK), code 0P2N, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ferrovial S.A. (0P2N) trades on the London Exchange in UK. It last closed at EUR 41.70 on 23 October 2026.
Its price-based Market X-Ray is 35 out of 100 (a weak price profile), ranking 2,879 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 22.3% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 17 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -22.3% | ||
| From 52-week high | -34.0% | ||
| Momentum | 28 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | -30.0% | ||
| 12-month return, skipping the last month | -22.3% | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 117.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.4% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 15.93M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 61 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +0.0% |
| 6 months | −30.0% |
| 1 year | −22.3% |
| 3 years | +58.7% |
| 5 years | +69.6% |
Signals
| 50-day / 200-day average | 44.59 / 53.64 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.4741 |
| 4 Dec 2025 | EUR 0.0655 |
| 24 Oct 2025 | EUR 0.4054 |
| 22 May 2025 | EUR 0.2705 |
| 13 Dec 2024 | EUR 0.0294 |
| 6 Nov 2024 | EUR 0.3908 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.